Avenue Therapeutics (ATXI) Competitors $0.76 0.00 (0.00%) As of 11:20 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ATXI vs. HOOK, PHXM, ALBT, IMCC, PCSA, VIVS, ADXN, APM, BCDA, and RNAZShould you be buying Avenue Therapeutics stock or one of its competitors? The main competitors of Avenue Therapeutics include HOOKIPA Pharma (HOOK), PHAXIAM Therapeutics (PHXM), Avalon GloboCare (ALBT), IM Cannabis (IMCC), Heatwurx (PCSA), VivoSim Labs (VIVS), Addex Therapeutics (ADXN), Aptorum Group (APM), BioCardia (BCDA), and TransCode Therapeutics (RNAZ). These companies are all part of the "pharmaceutical products" industry. Avenue Therapeutics vs. Its Competitors HOOKIPA Pharma PHAXIAM Therapeutics Avalon GloboCare IM Cannabis Heatwurx VivoSim Labs Addex Therapeutics Aptorum Group BioCardia TransCode Therapeutics HOOKIPA Pharma (NASDAQ:HOOK) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends. Does the media favor HOOK or ATXI? In the previous week, HOOKIPA Pharma's average media sentiment score of 0.00 equaled Avenue Therapeutics'average media sentiment score. Company Overall Sentiment HOOKIPA Pharma Neutral Avenue Therapeutics Neutral Which has preferable valuation & earnings, HOOK or ATXI? Avenue Therapeutics has lower revenue, but higher earnings than HOOKIPA Pharma. Avenue Therapeutics is trading at a lower price-to-earnings ratio than HOOKIPA Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHOOKIPA Pharma$9.35M1.21-$43.50M-$5.85-0.16Avenue TherapeuticsN/AN/A-$10.38M-$0.95-0.80 Which has more risk and volatility, HOOK or ATXI? HOOKIPA Pharma has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Avenue Therapeutics has a beta of -0.07, meaning that its stock price is 107% less volatile than the S&P 500. Do insiders and institutionals believe in HOOK or ATXI? 63.9% of HOOKIPA Pharma shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 3.3% of HOOKIPA Pharma shares are owned by insiders. Comparatively, 1.8% of Avenue Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is HOOK or ATXI more profitable? Avenue Therapeutics has a net margin of 0.00% compared to HOOKIPA Pharma's net margin of -785.66%. HOOKIPA Pharma's return on equity of -120.09% beat Avenue Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets HOOKIPA Pharma-785.66% -120.09% -77.14% Avenue Therapeutics N/A -471.57%-296.50% Do analysts rate HOOK or ATXI? HOOKIPA Pharma presently has a consensus price target of $4.50, indicating a potential upside of 383.87%. Given HOOKIPA Pharma's stronger consensus rating and higher probable upside, analysts plainly believe HOOKIPA Pharma is more favorable than Avenue Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HOOKIPA Pharma 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryHOOKIPA Pharma beats Avenue Therapeutics on 9 of the 13 factors compared between the two stocks. Get Avenue Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATXI vs. The Competition Export to ExcelMetricAvenue TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.42M$865.37M$5.79B$10.48BDividend YieldN/A4.84%5.61%4.57%P/E Ratio0.041.19348.8926.86Price / SalesN/A25.98522.55164.18Price / CashN/A17.6526.0131.15Price / Book0.406.4915.536.50Net Income-$10.38M-$3.95M$3.29B$271.42M7 Day Performance-9.02%0.95%200.87%3.69%1 Month Performance31.05%7.00%184.38%8.07%1 Year Performance-69.10%21.56%325.51%29.65% Avenue Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATXIAvenue Therapeutics1.1609 of 5 stars$0.76flatN/A-69.1%$2.42MN/A0.044HOOKHOOKIPA Pharma2.4581 of 5 stars$0.90-3.7%$4.50+402.5%-80.5%$10.92M$9.35M-0.15160Gap DownPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049ALBTAvalon GloboCare0.6623 of 5 stars$2.70+3.8%N/A-12.5%$10.37M$1.33M-0.145Gap UpIMCCIM Cannabis0.2882 of 5 stars$1.96+1.6%N/A-6.7%$10.29M$39.44M-3.63340Gap DownPCSAHeatwurx2.9791 of 5 stars$0.20+0.0%$1.00+398.8%-85.8%$10.10MN/A-0.0920Positive NewsVIVSVivoSim Labs0.263 of 5 stars$3.84-19.7%N/AN/A$9.98M$140K-0.3820ADXNAddex Therapeutics2.2671 of 5 stars$9.37-2.6%$30.00+220.2%-8.8%$9.93M$170.62K-27.5630Positive NewsUpcoming EarningsAPMAptorum Group0.2733 of 5 stars$1.85-5.6%N/A-18.2%$9.89MN/A0.0030Analyst UpgradeBCDABioCardia3.3388 of 5 stars$1.70-20.9%$25.00+1,370.6%-54.3%$9.86MN/A-0.9240Analyst ForecastHigh Trading VolumeRNAZTransCode Therapeutics2.0696 of 5 stars$11.67+6.6%$280.00+2,299.3%-99.9%$9.69MN/A0.009Positive NewsGap Up Related Companies and Tools Related Companies HOOKIPA Pharma Alternatives PHAXIAM Therapeutics Alternatives Avalon GloboCare Alternatives IM Cannabis Alternatives Heatwurx Alternatives VivoSim Labs Alternatives Addex Therapeutics Alternatives Aptorum Group Alternatives BioCardia Alternatives TransCode Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATXI) was last updated on 9/22/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe next AI Hype Spike is days away — don’t miss itOn this date, AI could trigger the kind of predictable surge that's already paid out 61%… 158%… and even 382% ...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avenue Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATXI Stock Alerts